There are 412 resources available
229P - The influence of ethnicity on cyclin-dependent kinase inhibitors efficacy: A systematic review and meta-analysis
Presenter: Aldo Caltavituro
Session: Lunch and Poster Display session
230P - HER2-low status in advanced breast cancer patients treated with CDK4/6 inhibitors: Is it predictive of outcome?
Presenter: Marcin Kubeczko
Session: Lunch and Poster Display session
232P - Assessment of treatment outcomes with everolimus and exemestane after CDK 4/6 inhibitors in hormone receptor-positive metastatic breast cancer patients in Clatterbridge Cancer Centre, Liverpool
Presenter: Smriti Gaur
Session: Lunch and Poster Display session
233P - Real-world first-line (1L) treatment selection for Australian patients (pts) with hormone receptor-positive advanced breast cancer (HR+ ABC)
Presenter: Vanessa Wong
Session: Lunch and Poster Display session
234P - A retrospective analysis to assess the impact of interaction between CDK4/6 inhibitors and proton pump inhibitors on clinical outcomes in metastatic breast cancer patients
Presenter: Maitreyee Rai
Session: Lunch and Poster Display session
235P - Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer
Presenter: Paola Zagami
Session: Lunch and Poster Display session
236P - Survival outcomes of patients (pts) with metastatic lobular breast cancer (mLBC) receiving cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and endocrine therapy (ET): A retrospective analysis
Presenter: Grazia Castellano
Session: Lunch and Poster Display session
237P - Overall survival (OS) estimation using target trial emulation of major randomized controlled trials (RCTs) with the ESME metastatic breast cancer (MBC) real-world data (RWD)
Presenter: Alison Antoine
Session: Lunch and Poster Display session
238P - Breast cancer drugs: FDA approval, development time, efficacy, clinical benefits, innovativeness, trials, endpoints, and price
Presenter: Julia Caroline Michaeli
Session: Lunch and Poster Display session
239P - Genomic landscape of metastatic ER+/HER2- breast cancer (BC) with loss of estrogen (ER) and/or progesterone (PR) receptor
Presenter: Cristina Guarducci
Session: Lunch and Poster Display session